NCT05915182 - Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece | Biotech Hunter

Enrollment

218

Participants

Timeline

Start Date

July 21, 2023

Primary Completion Date

March 28, 2025

Study Completion Date

March 28, 2025

Conditions

Pulmonary Disease, Chronic Obstructive (COPD)

Interventions

COMBINATION_PRODUCT

Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler

Participants with moderate to severe Chronic Obstructive Pulmonary Disease

Trial Locations (15)

Research Site, Athens

Research Site, Athens

Research Site, Athens

Research Site, Athens

Research Site, Pátrai

Research Site, Pátrai

Research Site, Larissa

Research Site, Ioannina

Research Site, Corfu

Research Site, Thessaloniki

Research Site, Thessaloniki

Research Site, Alexandroupoli

Research Site, Crete

Research Site, Crete

Research Site, Crete